Ged Giblin
Corporate Officer/Principal en Convergence Pharmaceuticals Ltd. .
Perfil
Ged Giblin is currently the Head-Chemistry & Preclinical Development at Convergence Pharmaceuticals Ltd.
He previously worked as the Head-Medicinal Chemistry at GlaxoSmithKline (Pharmaceutical Operations).
Cargos activos de Ged Giblin
| Empresas | Cargo | Inicio |
|---|---|---|
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | 06/10/2010 |
Antiguos cargos conocidos de Ged Giblin.
| Empresas | Cargo | Fin |
|---|---|---|
| GlaxoSmithKline (Pharmaceutical Operations) | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| GlaxoSmithKline (Pharmaceutical Operations) |
- Bolsa de valores
- Insiders
- Ged Giblin